Cargando…
Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor
BACKGROUND & AIMS: A significant benefit of imatinib adjuvant therapy for patients with high risk gastrointestinal stromal tumors (GIST) has been confirmed. However, the effect of imatinib adjuvant therapy for intermediate-risk GIST has not been well studied. In this article, we compare differen...
Autores principales: | Fu, Yang, Hao, He, Guo, Luwei, Yang, Ge, Zhang, Xiefu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5354647/ https://www.ncbi.nlm.nih.gov/pubmed/28052037 http://dx.doi.org/10.18632/oncotarget.14359 |
Ejemplares similares
-
Prognostic Value of Fibrinogen and Lymphocyte Count in Intermediate and High Risk Gastrointestinal Stromal Tumors
por: Guo, Yinghao, et al.
Publicado: (2020) -
Noncoding RNAs in Drug Resistance of Gastrointestinal Stromal Tumor
por: Li, Jiehan, et al.
Publicado: (2022) -
Chinese Pedigree with Hereditary Gastrointestinal Stromal Tumors: A Case Report and Literature Review
por: Ge, Qichao, et al.
Publicado: (2023) -
Naples prognostic score, a novel prognostic score for patients with high- and intermediate-risk gastrointestinal stromal tumours after surgical resection
por: Wu, Hao, et al.
Publicado: (2022) -
Prognostic value of Onodera’s nutritional index for intermediate- and high-risk gastrointestinal stromal tumors treated with or without tyrosine kinase inhibitors
por: Wang, Feng, et al.
Publicado: (2021)